No Data
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
AIRDOC-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATIONTO THE ANNUAL REPORT OF THE COMPANYFOR THE YEAR ENDED DECEMBER 31, 2023
AIRDOC-B: 2024 INTERIM REPORT
Eagle Eye Technology (02251.HK): The gradual release of growth elasticity, looking at AI diagnosis and treatment integrated commercial application models.
In recent years, AI technology has triggered an unprecedented revolution in the medical field, from assisting in diagnosis to empowering medical imaging, and even to drug development. The power of AI is gradually permeating and reshaping every corner of the medical industry. In this context, how can investors seize the deterministic opportunities in the AI medical field? Which companies can stand out and become the backbone of the industry? In the eyes of industry observers, AI medical companies that are the first to explore commercial landing paths and have self-regenerating capabilities are more investment-worthy. These companies generally have strong research and development capabilities and market insights, allowing them to stand firm in intense market competition.
Express News | Airdoc Technology 2024 Interim Results: Solid Growth in Revenue and Gross Profit
Eagle Eye Technology - B (02251): Wu Gangping resigns as an independent executive director.
Eagle Eye Technology -B (02251) announced that on the date of this announcement, Wu Gangping has resigned as an independent executive director in order to devote himself to...
No Data
No Data